Privia Health Group (NASDAQ:PRVA) Rating Reiterated by Credit Suisse Group

Privia Health Group (NASDAQ:PRVA – Get Rating)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Credit Suisse Group in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $41.00 price objective on the stock. Credit Suisse Group’s price objective suggests a potential upside of 44.67% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. SVB Leerink cut their target price on Privia Health Group from $46.00 to $39.00 and set an “outperform” rating on the stock in a research report on Friday, November 11th. Canaccord Genuity Group reduced their price objective on shares of Privia Health Group from $50.00 to $43.00 in a research report on Friday, November 11th. BTIG Research dropped their target price on shares of Privia Health Group from $45.00 to $40.00 in a research report on Monday, January 9th. UBS Group began coverage on shares of Privia Health Group in a research note on Thursday, December 8th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Truist Financial decreased their price target on shares of Privia Health Group to $41.00 in a research note on Thursday, November 17th. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $38.93.

Privia Health Group Stock Down 0.3 %

PRVA stock opened at $28.34 on Tuesday. The company’s fifty day simple moving average is $25.98 and its 200 day simple moving average is $29.51. Privia Health Group has a 12-month low of $17.99 and a 12-month high of $44.64. The firm has a market cap of $3.26 billion, a price-to-earnings ratio of -257.64, a PEG ratio of 5.91 and a beta of 0.79.

Insider Buying and Selling at Privia Health Group

In other Privia Health Group news, CEO Matthew Shawn Morris sold 44,340 shares of Privia Health Group stock in a transaction dated Tuesday, March 7th. The stock was sold at an average price of $28.48, for a total transaction of $1,262,803.20. Following the completion of the transaction, the chief executive officer now owns 121,739 shares in the company, valued at approximately $3,467,126.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Matthew Shawn Morris sold 44,340 shares of the business’s stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $28.48, for a total value of $1,262,803.20. Following the transaction, the chief executive officer now owns 121,739 shares in the company, valued at approximately $3,467,126.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Thomas Bartrum sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $28.55, for a total value of $428,250.00. Following the completion of the transaction, the executive vice president now owns 91,355 shares in the company, valued at approximately $2,608,185.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 294,253 shares of company stock worth $7,936,737. Insiders own 57.60% of the company’s stock.

Hedge Funds Weigh In On Privia Health Group

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Privia Health Group by 7.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,824,724 shares of the company’s stock worth $164,331,000 after buying an additional 321,734 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Privia Health Group by 16.8% in the 3rd quarter. BlackRock Inc. now owns 3,283,793 shares of the company’s stock worth $111,846,000 after purchasing an additional 471,296 shares during the period. Millennium Management LLC raised its holdings in shares of Privia Health Group by 183.8% in the 4th quarter. Millennium Management LLC now owns 2,996,072 shares of the company’s stock worth $68,041,000 after purchasing an additional 1,940,218 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of Privia Health Group by 0.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,793,623 shares of the company’s stock worth $63,444,000 after purchasing an additional 18,752 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Privia Health Group by 71.8% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,780,204 shares of the company’s stock worth $80,960,000 after purchasing an additional 1,162,270 shares during the period. Hedge funds and other institutional investors own 66.83% of the company’s stock.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.